Could a lung drug save kidneys in liver patients?
NCT ID NCT06256432
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether ambrisentan, a drug approved for lung blood pressure, can help patients with hepatorenal syndrome—a serious kidney problem that can occur in advanced liver cirrhosis. About 54 hospitalized adults will receive either ambrisentan or the standard drug terlipressin. The goal is to see if ambrisentan improves kidney function and reduces death risk, with treatment continuing at home for up to 60 days.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ambrisentan
What this could lead to
If it works, this could offer a new treatment option for hepatorenal syndrome, potentially improving kidney function and survival in patients with advanced liver disease.
What could go wrong
This is an early Phase 2 trial with only 54 participants, so results may not apply to everyone. Ambrisentan may not work better than the current standard treatment, and side effects are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE KIDNEY INJURY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
All India Institute of Medical Sciences
New Delhi, National Capital Territory of Delhi, 110029, India
-
Asian Institute of Gastroenterology (AIG)
Hyderabad, Telangana, 500082, India
-
Aster CMI Hospital
Bangalore, Karnataka, 560092, India
-
Ganesh Shankar Vidyarthi Memorial (GSVM) Medical College
Kanpur, Uttar Pradesh, 208002, India
-
Medanta Multi Super Specialty Hospital
Lucknow, Uttar Pradesh, 226030, India
-
Sir HN Reliance Hospital Foundation
Mumbai, Maharashtra, 400004, India